|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Petrushnko W, Gundara JS, De Reuver PR,
O'Grady G, Samra JS and Mittal A: Systematic review of
peri-operative prognostic biomarkers in pancreatic ductal
adenocarcinoma. HPB (Oxford). 18:652–663. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Board PATE: Pancreatic Cancer Treatment
(PDQ@): Health professional version. National Cancer Institute,
2019.
|
|
5
|
Mizrahi JD, Surana R, Valle JW and Shroff
RT: Pancreatic cancer. Lancet. 395:2008–2020. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bockhorn M, Uzunoglu FG, Adham M, Imrie C,
Milicevic M, Sandberg AA, Asbun HJ, Bassi C, Büchler M, Charnley
RM, et al: Borderline resectable pancreatic cancer: A consensus
statement by the international study group of pancreatic surgery
(ISGPS). Surgery. 155:977–988. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Isaji S, Mizuno S, Windsor JA, Bassi C,
Fernández-Del Castillo C, Hackert T, Hayasaki A, Katz MHG, Kim SW,
Kishiwada M, et al: International consensus on definition and
criteria of borderline resectable pancreatic ductal adenocarcinoma
2017. Pancreatology. 18:2–11. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hidalgo M, Cascinu S, Kleeff J, Labianca
R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL and Heinemann V:
Addressing the challenges of pancreatic cancer: Future directions
for improving outcomes. Pancreatology. 15:8–18. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Eberlin LS, Margulis K, Planell-Mendez I,
Zare RN, Tibshirani R, Longacre TA, Jalali M, Norton JA and
Poultsides GA: Pancreatic cancer surgical resection margins:
Molecular assessment by mass spectrometry imaging. PLoS Med.
13(e1002108)2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Piciucchi M, Capurso G, Valente R, Larghi
A, Archibugi L, Signoretti M, Stigliano S, Zerboni G, Barucca V, La
Torre M, et al: Early onset pancreatic cancer: Risk factors,
presentation and outcome. Pancreatology. 15:151–155.
2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Pontén F, Schwenk JM, Asplund A and
Edqvist PH: The human protein atlas as a proteomic resource for
biomarker discovery. J Intern Med. 270:428–446. 2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tzeng CW, Fleming JB, Lee JE, Xiao L,
Pisters PW, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR,
Fogelman DR, et al: Defined clinical classifications are associated
with outcome of patients with anatomically resectable pancreatic
adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol.
19:2045–2053. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Asaoka T, Miyamoto A, Maeda S, Tsujie M,
Hama N, Yamamoto K, Miyake M, Haraguchi N, Nishikawa K, Hirao M, et
al: Prognostic impact of preoperative NLR and CA19-9 in pancreatic
cancer. Pancreatology. 16:434–440. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sugiura T, Uesaka K, Kanemoto H, Mizuno T,
Sasaki K, Furukawa H, Matsunaga K and Maeda A: Serum CA19-9 is a
significant predictor among preoperative parameters for early
recurrence after resection of pancreatic adenocarcinoma. J
Gastrointest Surg. 16:977–985. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Waraya M, Yamashita K, Katagiri H, Ishii
K, Takahashi Y, Furuta K and Watanabe M: Preoperative serum CA19-9
and dissected peripancreatic tissue margin as determiners of
long-term survival in pancreatic cancer. Ann Surg Oncol.
16:1231–1240. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Meng Q, Shi S, Liang C, Liang D, Xu W, Ji
S, Zhang B, Ni Q, Xu J and Yu X: Diagnostic and prognostic value of
carcinoembryonic antigen in pancreatic cancer: A systematic review
and meta-analysis. Onco Targets Ther. 10:4591–4598. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Gold P and Freedman SO: Specific
carcinoembryonic antigens of the human digestive system. J Exp Med.
122:467–481. 1965.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Molina R, Barak V, van Dalen A, Duffy MJ,
Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G and
Stieber P: Tumor markers in breast cancer-European group on tumor
markers recommendations. Tumour Biol. 26:281–293. 2005.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Grunnet M and Sorensen JB:
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung
Cancer. 76:138–143. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Juweid M, Sharkey RM, Behr T, Swayne LC,
Rubin AD, Herskovic T, Hanley D, Markowitz A, Dunn R, Siegel J, et
al: Improved detection of medullary thyroid cancer with
radiolabeled antibodies to carcinoembryonic antigen. J Clin Oncol.
14:1209–1217. 1996.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Nazli O, Bozdag AD, Tansug T, Kir R and
Kaymak E: The diagnostic importance of CEA and CA 19-9 for the
early diagnosis of pancreatic carcinoma. Hepatogastroenterology.
47:1750–1752. 2000.PubMed/NCBI
|
|
22
|
Satake K, Chung YS, Yokomatsu H, Nakata B,
Tanaka H, Sawada T, Nishiwaki H and Umeyama K: A clinical
evaluation of various tumor markers for the diagnosis of pancreatic
cancer. Int J Pancreatol. 7:25–36. 1990.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Imaoka H, Mizuno N, Hara K, Hijioka S,
Tajika M, Tanaka T, Ishihara M, Hirayama Y, Hieda N, Yoshida T, et
al: Prognostic impact of carcinoembryonic antigen (CEA) on patients
with metastatic pancreatic cancer: A retrospective cohort study.
Pancreatology. 16:859–864. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Rhodes JM and Ching CK: Serum diagnostic
tests for pancreatic cancer. Baillieres Clin Gastroenterol.
4:833–852. 1990.PubMed/NCBI View Article : Google Scholar
|
|
25
|
National Comprehensive Cancer Network:
NCCN clinical practive guideline in oncology (NCCN
Guidelines®): Pancreatic adenocarcinoma. Version 1.2021,
October, 2021.
|
|
26
|
Hata S, Sakamoto Y, Yamamoto Y, Nara S,
Esaki M, Shimada K and Kosuge T: Prognostic impact of postoperative
serum CA 19-9 levels in patients with resectable pancreatic cancer.
Ann Surg Oncol. 19:636–641. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Takasaki H, Uchida E, Tempero MA, Burnett
DA, Metzgar RS and Pour PM: Correlative study on expression of CA
19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer
patients. Cancer Res. 48:1435–1438. 1988.PubMed/NCBI
|
|
28
|
Aoki H, Ohnishi H, Hama K, Ishijima T,
Satoh Y, Hanatsuka K, Ohashi A, Wada S, Miyata T, Kita H, et al:
Autocrine loop between TGF-beta1 and IL-1beta through Smad3- and
ERK-dependent pathways in rat pancreatic stellate cells. Am J
Physiol Cell Physiol. 290:C1100–C1108. 2006.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tanaka M, Chari S, Adsay V, Fernandez-del
Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K and Matsuno
S: International Association of Pancreatology. International
consensus guidelines for management of intraductal papillary
mucinous neoplasms and mucinous cystic neoplasms of the pancreas.
Pancreatology. 6:17–32. 2006.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Goonetilleke KS and Siriwardena AK:
Systematic review of carbohydrate antigen (CA 19-9) as a
biochemical marker in the diagnosis of pancreatic cancer. Eur J
Surg Oncol. 33:266–270. 2007.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kobayashi T, Kawa S, Tokoo M, Oguchi H,
Kiyosawa K, Furuta S, Kanai M and Homma T: Comparative study of
CA-50 (time-resolved fluoroimmunoassay), Span-1, and CA19-9 in the
diagnosis of pancreatic cancer. Scand J Gastroenterol. 26:787–797.
1991.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Palmquist C, Dehlendorff C, Calatayud D,
Hansen CP, Hasselby JP and Johansen JS: Prediction of
unresectability and prognosis in patients undergoing surgery on
suspicion of pancreatic cancer using carbohydrate antigen 19-9,
interleukin 6, and YKL-40. Pancreas. 49:53–61. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Tian F, Appert HE, Myles J and Howard JM:
Prognostic value of serum CA 19-9 levels in pancreatic
adenocarcinoma. Ann Surg. 215:350–355. 1992.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Liu L, Xu H, Wang W, Wu C, Chen Y, Yang J,
Cen P, Xu J, Liu C, Long J, et al: A preoperative serum signature
of CEA+/CA125+/CA19-9 ≥ 1000 U/ml indicates poor outcome to
pancreatectomy for pancreatic cancer. Int J Cancer. 136:2216–2227.
2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chari ST, Kelly K, Hollingsworth MA,
Thayer SP, Ahlquist DA, Andersen DK, Batra SK, Brentnall TA, Canto
M, Cleeter DF, et al: Early detection of sporadic pancreatic
cancer: Summative review. Pancreas. 44:693–712. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Giannis D, Moris D and Barbas AS:
Diagnostic, predictive and prognostic molecular biomarkers in
pancreatic cancer: An overview for clinicians. Cancers (Basel).
13(1071)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
van Manen L, Groen JV, Putter H,
Vahrmeijer AL, Swijnenburg RJ, Bonsing BA and Mieog JSD: Elevated
CEA and CA19-9 serum levels independently predict advanced
pancreatic cancer at diagnosis. Biomarkers. 25:186–193.
2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474.
2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Poruk KE, Gay DZ, Brown K, Mulvihill JD,
Boucher KM, Scaife CL, Firpo MA and Mulvihill SJ: The clinical
utility of CA 19-9 in pancreatic adenocarcinoma: Diagnostic and
prognostic updates. Curr Mol Med. 13:340–351. 2013.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Ni XG, Bai XF, Mao YL, Shao YF, Wu JX,
Shan Y, Wang CF, Wang J, Tian YT, Liu Q, et al: The clinical value
of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of
pancreatic cancer. Eur J Surg Oncol. 31:164–169. 2005.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
US Preventive Services Task Force. Owens
DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry
SJ, Doubeni CA, Epling JW Jr, et al: Screening for pancreatic
cancer: US preventive services task force reaffirmation
recommendation statement. JAMA. 322:438–444. 2019.
|
|
43
|
He XY and Yuan YZ: Advances in pancreatic
cancer research: Moving towards early detection. World J
Gastroenterol. 20:11241–11248. 2014.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Okano K and Suzuki Y: Strategies for early
detection of resectable pancreatic cancer. World J Gastroenterol.
20:11230–11240. 2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Lee KJ, Yi SW, Chung MJ, Park SW, Song SY,
Chung JB and Park JY: Serum CA 19-9 and CEA levels as a prognostic
factor in pancreatic adenocarcinoma. Yonsei Med J. 54:643–649.
2013.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Koprowski H, Steplewski Z, Mitchell K,
Herlyn M, Herlyn D and Fuhrer P: Colorectal carcinoma antigens
detected by hybridoma antibodies. Somatic Cell Genet. 5:957–971.
1979.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Reitz D, Gerger A, Seidel J, Kornprat P,
Samonigg H, Stotz M, Szkandera J and Pichler M: Combination of
tumour markers CEA and CA19-9 improves the prognostic prediction in
patients with pancreatic cancer. J Clin Pathol. 68:427–433.
2015.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Kim YC, Kim HJ, Park JH, Park DI, Cho YK,
Sohn CI, Jeon WK, Kim BI and Shin JH: Can preoperative CA19-9 and
CEA levels predict the resectability of patients with pancreatic
adenocarcinoma? J Gastroenterol Hepatol. 24:1869–1875.
2009.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Mehta J, Prabhu R, Eshpuniyani P,
Kantharia C and Supe A: Evaluating the efficacy of tumor markers CA
19-9 and CEA to predict operability and survival in pancreatic
malignancies. Trop Gastroenterol. 31:190–194. 2010.PubMed/NCBI
|
|
50
|
Xu HX, Liu L, Xiang JF, Wang WQ, Qi ZH, Wu
CT, Liu C, Long J, Xu J, Ni QX and Yu XJ: Postoperative serum CEA
and CA125 levels are supplementary to perioperative CA19-9 levels
in predicting operative outcomes of pancreatic ductal
adenocarcinoma. Surgery. 161:373–384. 2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Salmiheimo A, Mustonen H, Stenman UH,
Puolakkainen P, Kemppainen E, Seppänen H and Haglund C: Systemic
inflammatory response and elevated tumour markers predict worse
survival in resectable pancreatic ductal adenocarcinoma. PLoS One.
11(e0163064)2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Distler M, Pilarsky E, Kersting S and
Grützmann R: Preoperative CEA and CA 19-9 are prognostic markers
for survival after curative resection for ductal adenocarcinoma of
the pancreas-a retrospective tumor marker prognostic study. Int J
Surg. 11:1067–1072. 2013.PubMed/NCBI View Article : Google Scholar
|
